GHK-Cu Peptide: Autoimmune Skin Evidence Guide [2026]

GHK-Cu is a copper-binding tripeptide that the human body produces naturally and that declines with age. In the most comprehensive gene expression study, it modulated over 4,000 human genes, switching on anti-inflammatory and tissue repair pathways while suppressing inflammatory ones. For autoimmune skin conditions like psoriasis, eczema, and alopecia areata, GHK-Cu targets the right mechanisms: NF-kB suppression, collagen remodeling, antioxidant defense. The problem is that nearly all of this evidence comes from cell studies and gene expression analysis. No clinical trial has tested GHK-Cu for any autoimmune skin condition. This guide grades the evidence honestly, condition by condition, and explains what the data actually supports.

What Is GHK-Cu?

GHK-Cu (glycyl-L-histidyl-L-lysine copper) is a naturally occurring tripeptide first isolated from human plasma by Loren Pickart in 1973. It consists of three amino acids bound to a copper(II) ion. The molecular weight is approximately 403 daltons, making it one of the smallest biologically active peptides in therapeutic use.

In human plasma, GHK-Cu concentration is approximately 200 ng/mL at age 20. By age 60, levels drop to roughly 80 ng/mL. This age-related decline correlates with reduced wound healing capacity, thinning skin, and diminished tissue repair. Whether the decline is causative or merely correlative remains an open question, but the pattern is consistent across studies.

GHK-Cu's biological role extends far beyond copper delivery. The peptide-copper complex acts as a signaling molecule that enters cells and modulates gene expression at the transcriptional level. This is what separates it from copper supplements: you cannot replicate GHK-Cu's effects by taking copper alone. The peptide structure is the active component, with copper serving as both a structural element and a cofactor for downstream enzymatic reactions.

The 4,000-Gene Discovery

The landmark finding that transformed GHK-Cu from a cosmetic ingredient to a compound of broader scientific interest came from Loren Pickart and colleagues. Using the Broad Institute's Connectivity Map (cMap), they compared GHK-Cu's gene expression signature against thousands of other compounds. The results were striking: GHK-Cu modulated the expression of 4,048 human genes, representing approximately 31% of the human genome.

The directional pattern was consistent. GHK-Cu upregulated genes associated with tissue repair, antioxidant defense, and anti-inflammatory signaling. It downregulated genes associated with inflammation, fibrosis, and tissue destruction. Critically, the gene expression profile of GHK-Cu resembled the opposite of the profile seen in aggressive metastatic cancer, which prompted interest from oncology researchers.

For autoimmune skin conditions, the relevant gene clusters include TGF-beta superfamily genes (tissue remodeling), TIMP metalloproteinase inhibitors (extracellular matrix protection), SOD and other antioxidant genes (oxidative stress defense), and NF-kB pathway inhibitors (inflammation control). Each of these gene clusters addresses a mechanism directly involved in psoriasis, eczema, or alopecia pathology.

How GHK-Cu Works in Skin

Collagen Remodeling and Barrier Repair

GHK-Cu stimulates collagen synthesis, specifically types I and III, which form the structural framework of the dermis. It simultaneously activates matrix metalloproteinases (MMPs) that break down damaged collagen and upregulates TIMPs that prevent excessive collagen degradation. This dual action does not simply build more collagen. It remodels the existing extracellular matrix, replacing damaged protein structures with properly organized new ones.

For autoimmune skin conditions, this remodeling function matters because the inflammatory cascade damages the dermal architecture. In psoriasis, chronic inflammation leads to disordered keratinocyte proliferation and abnormal skin structure. In eczema, barrier dysfunction allows allergens and pathogens to penetrate the epidermis, triggering further immune activation. GHK-Cu's ability to rebuild organized dermal structure could theoretically break this cycle of damage and inflammation.

Decorin, a small proteoglycan that regulates collagen fibril organization, is also upregulated by GHK-Cu. Decorin plays a role in TGF-beta signaling modulation. In fibrotic skin conditions like scleroderma, TGF-beta drives excessive collagen deposition. GHK-Cu's effect on decorin suggests it promotes healthy collagen organization rather than fibrosis, though this distinction has only been demonstrated at the gene expression level.

NF-kB Suppression

Nuclear factor kappa B (NF-kB) is the master inflammatory transcription factor implicated in virtually every autoimmune condition. In psoriasis, NF-kB activation drives keratinocyte hyperproliferation and inflammatory cytokine production (TNF-alpha, IL-17, IL-23). In eczema, it amplifies the Th2-driven inflammatory cascade. In alopecia areata, NF-kB contributes to the collapse of immune privilege around hair follicles.

GHK-Cu suppresses NF-kB through gene modulation rather than direct pathway blockade. The Connectivity Map data showed downregulation of multiple NF-kB-related gene networks. This is a softer mechanism than direct NF-kB inhibitors (like the approach used by KPV peptide, which physically blocks NF-kB nuclear translocation). Whether GHK-Cu's gene-level modulation translates to clinically meaningful NF-kB suppression in inflamed skin has not been measured in vivo.

This is the central limitation of the GHK-Cu story for autoimmune conditions. Gene expression changes in cell culture do not automatically produce therapeutic effects in living tissue. The gap between "this compound changes gene expression in a favorable direction" and "this compound improves autoimmune skin disease" is the gap that no clinical trial has bridged.

Antioxidant Defense

Oxidative stress is a driver of tissue damage in every autoimmune skin condition. GHK-Cu upregulates superoxide dismutase (SOD), a key antioxidant enzyme that neutralizes superoxide radicals. It also modulates glutathione-related genes and other components of the cellular antioxidant defense system.

In vitiligo, where melanocytes are destroyed by immune attack partly mediated by oxidative stress, this antioxidant mechanism is particularly relevant. Copper itself is a cofactor for tyrosinase, the enzyme required for melanin synthesis. GHK-Cu could theoretically support melanocyte survival through both antioxidant protection and copper delivery. No study has tested this hypothesis directly.

Mast Cell Stabilization

GHK-Cu has demonstrated mast cell stabilizing properties in cell culture. Mast cells release histamine and inflammatory mediators that drive the itch-scratch cycle in eczema and contribute to inflammation in psoriasis. Stabilizing mast cells (preventing degranulation) is the mechanism behind antihistamines and mast cell stabilizers like cromolyn sodium.

The clinical significance of GHK-Cu's mast cell effects at topical concentrations is unknown. Cosmetic studies have reported reduced skin redness and irritation, which is consistent with mast cell stabilization, but these were not designed to measure the mechanism directly.

Evidence by Autoimmune Skin Condition

Psoriasis (Grade C)

Psoriasis involves NF-kB-driven keratinocyte hyperproliferation, IL-17/IL-23 axis activation, and TNF-alpha overproduction. GHK-Cu's gene expression profile addresses the NF-kB and TNF-alpha components. The TGF-beta modulation could theoretically normalize keratinocyte differentiation, which is disordered in psoriatic plaques.

The specific gap: no animal model of psoriasis has been treated with GHK-Cu. The gene expression data is from human cell culture using the Connectivity Map approach, which identifies patterns across thousands of genes but does not prove clinical efficacy. This is the difference between Grade C (mechanistic relevance, no direct evidence) and Grade B (direct evidence from at least one controlled study).

For psoriasis patients, the strongest topical evidence for non-pharmaceutical intervention remains vitamin D analogs (calcipotriol, Grade A) and UV phototherapy (Grade A). Curcumin has modest evidence for systemic inflammation reduction. GHK-Cu could be considered as an adjunct in a broader protocol, but it should not replace therapies with established clinical evidence.

One consideration specific to psoriasis: KPV peptide also targets NF-kB but through direct pathway inhibition rather than gene modulation. For psoriasis patients considering peptide therapy as part of their broader protocol, KPV's mechanism is more directly aligned with the NF-kB overactivation that drives plaque formation, though KPV also lacks human psoriasis trial data.

Eczema and Atopic Dermatitis (Grade C)

Eczema is a barrier disease with an immune amplification loop. Filaggrin gene mutations impair the skin barrier, allowing allergen penetration, which triggers Th2 immune activation, which produces inflammation that further damages the barrier. Breaking this cycle at any point can reduce symptoms.

GHK-Cu's barrier repair mechanisms (collagen remodeling, decorin upregulation, glycosaminoglycan synthesis) target the structural side of the equation. The mast cell stabilization and NF-kB suppression address the inflammatory amplification. In theory, GHK-Cu addresses both arms of the eczema cycle simultaneously.

The practical evidence comes from cosmetic use, where GHK-Cu serums at 0.1 to 1% concentrations improve skin texture, reduce fine lines, and enhance overall skin quality. These cosmetic outcomes suggest barrier improvement but are not equivalent to eczema treatment data. Cosmetic studies typically exclude people with active skin disease, which means the population most relevant to eczema has never been formally studied.

The TIMP-1 upregulation by GHK-Cu is relevant here. TIMP-1 (tissue inhibitor of metalloproteinase 1) prevents excessive extracellular matrix degradation. In eczema, the barrier is being actively degraded by inflammatory enzymes. Shifting the balance toward matrix preservation (via TIMP-1) over matrix destruction (via MMPs) could protect the barrier during flares. This remains theoretical.

For eczema patients building a protocol, the autoimmune diet guide covers elimination strategies with stronger evidence, and vitamin D supplementation has Grade A evidence for immune modulation.

Alopecia Areata (Grade C)

Alopecia areata is an autoimmune attack on hair follicles driven by the collapse of "immune privilege," a mechanism that normally shields follicles from immune surveillance. CD8+ T cells infiltrate the follicle bulb, producing interferon-gamma and other cytokines that halt the hair growth cycle. The follicles are not destroyed, which is why regrowth is possible when the immune attack subsides.

GHK-Cu's relevance to alopecia comes from two directions. First, Pyo et al. (2007) demonstrated in hair follicle organ culture that GHK-Cu stimulated hair growth and increased follicle size. The study used isolated human hair follicles (not an animal model) and found that GHK-Cu at appropriate concentrations promoted the proliferation of dermal papilla cells, the stem cell population that drives hair cycling.

Second, GHK-Cu's anti-inflammatory gene modulation could theoretically reduce the immune attack on follicles. NF-kB suppression, SOD upregulation, and TGF-beta modulation are all relevant to the immune privilege collapse that initiates alopecia areata. But the Pyo 2007 study was not conducted in an autoimmune context. The follicles were healthy, not under immune attack. Stimulating growth in healthy follicles is fundamentally different from restoring growth in follicles under active autoimmune assault.

Some practitioners combine GHK-Cu with microneedling for alopecia areata, applying the serum immediately after creating micro-channels in the scalp. The rationale is that microneedling both enhances peptide penetration and triggers a wound healing response that may help restore immune privilege. This approach has no controlled study behind it, though microneedling alone has shown promise for androgenetic alopecia (a non-autoimmune condition) in small trials.

For alopecia areata patients, the supplement evidence guide and natural remedies overview cover interventions with stronger clinical data, including zinc (Grade A for deficiency), vitamin D (Grade B), and topical rosemary oil (Grade B for androgenetic alopecia, unproven for areata).

Scleroderma (Grade C)

Scleroderma (systemic sclerosis) involves excessive collagen deposition driven by overactive TGF-beta signaling. This creates the paradox for GHK-Cu: a compound that promotes collagen synthesis might seem contraindicated for a condition defined by too much collagen. The nuance is that GHK-Cu promotes collagen remodeling, not simply collagen accumulation.

The gene expression data shows that GHK-Cu upregulates both collagen synthesis genes and matrix-degrading enzymes (MMPs). It also upregulates decorin, which is a natural inhibitor of TGF-beta signaling. The net effect, at least in gene expression studies, appears to be organized remodeling rather than disordered fibrosis. In scleroderma, the problem is not just excess collagen but excess disorganized collagen driven by unchecked TGF-beta.

This is entirely theoretical. No scleroderma cell model, animal model, or clinical study has examined GHK-Cu. The gap between gene expression patterns and clinical outcomes in fibrotic disease is particularly wide because fibrosis involves complex tissue-level dynamics that cell culture cannot replicate.

Vitiligo (Grade C)

Vitiligo involves autoimmune destruction of melanocytes, the pigment-producing cells in the skin. Oxidative stress is a central mechanism: reactive oxygen species damage melanocytes, which then become targets for T-cell attack. GHK-Cu's SOD upregulation and broader antioxidant gene modulation could theoretically protect surviving melanocytes from oxidative damage.

Copper itself is relevant because it serves as a cofactor for tyrosinase, the rate-limiting enzyme in melanin production. Some vitiligo researchers have examined copper status in patients, finding lower serum copper levels in vitiligo populations. Whether delivering copper via GHK-Cu to melanocytes would improve pigment production is speculative.

The honest assessment: GHK-Cu's mechanisms are tangentially relevant to vitiligo, but the condition requires immune tolerance restoration more than tissue repair. Vitamin D and UV phototherapy (Grade A) address vitiligo through immune modulation, which is the more fundamental need.

The FDA Reclassification Context

In February 2026, the FDA under Robert F. Kennedy Jr. initiated a reclassification process for several peptide compounds that had been restricted under the previous administration's enforcement actions. This reclassification primarily affected compounding pharmacy access to peptides like BPC-157 and thymosin alpha 1 that had been on the FDA's "difficult to compound" list.

GHK-Cu was not directly targeted by these enforcement actions because it already existed in a regulatory gray zone. As a cosmetic ingredient, GHK-Cu at low concentrations (0.1 to 1%) is sold freely in skincare products without FDA therapeutic approval. At higher concentrations, compounding pharmacies can prepare GHK-Cu formulations with a prescription, subject to state pharmacy board regulation.

The reclassification does not change GHK-Cu's evidence base. No new clinical data emerged from the regulatory shift. What changed is the broader regulatory environment for peptide compounds, which has increased public interest in peptides as a category and expanded access through compounding pharmacies. For autoimmune patients, the fundamental question remains the same: does the evidence support using this compound for my condition? For GHK-Cu and autoimmune skin disease, the answer remains "not yet."

GHK-Cu Compared to Other Peptides for Skin

Several peptides are discussed in autoimmune skin contexts. They work through different mechanisms, which matters for protocol design.

GHK-Cu modulates gene expression broadly (4,000+ genes), promotes collagen remodeling, suppresses NF-kB at the transcriptional level, and upregulates antioxidant defense. It is available topically. The evidence base is gene expression and cosmetic studies.

KPV directly inhibits NF-kB nuclear translocation and blocks caspase-1 activation. It is primarily studied for gut inflammation but has mechanistic relevance for skin. For psoriasis and eczema, KPV's more direct NF-kB inhibition may be more potent than GHK-Cu's gene-level modulation, though neither has skin disease clinical data.

TB-500 promotes tissue repair through actin regulation, cell migration, and angiogenesis. It is more relevant for joint and wound repair than for autoimmune skin conditions. TB-500 carries a theoretical cancer concern through its angiogenic mechanism, which GHK-Cu does not share. Interestingly, GHK-Cu's gene expression profile opposes metastatic cancer signatures, which is the opposite pattern.

Thymosin alpha 1 is a true immune modulator that rebalances Th1/Th2 responses and restores regulatory T-cell function. It is approved in 35+ countries (not the US) and has the strongest clinical safety data of any therapeutic peptide. For autoimmune conditions, TA1 addresses the immune dysregulation directly. GHK-Cu addresses tissue damage and repair. They target different aspects of the problem.

For patients considering peptide therapy for autoimmune conditions, GHK-Cu has one practical advantage: topical application. Most therapeutic peptides require injection, which creates access and compliance barriers. GHK-Cu can be applied directly to affected skin, which at minimum delivers it to the relevant tissue. Whether it reaches therapeutic concentrations through topical application is uncertain.

Dosage and Administration

All dosing information comes from cosmetic research, practitioner protocols, and community reports. No clinical trial has established optimal doses for any autoimmune skin condition.

Topical (cosmetic grade, OTC): 0.1 to 1% GHK-Cu serum applied once or twice daily. This is the most accessible form. Cosmetic studies at these concentrations show improvements in skin texture, firmness, and fine lines over 8 to 12 weeks. Whether this concentration achieves meaningful gene modulation in inflamed autoimmune skin is unknown.

Topical (compounded, Rx): 1 to 3% GHK-Cu cream or serum, available through compounding pharmacies with a prescription. Higher concentrations are used by practitioners targeting specific skin conditions rather than general cosmetic improvement. No controlled comparison of concentrations has been published.

Subcutaneous injection: 1 to 2 mg per day, typically for 4 to 8 weeks. Used by functional medicine practitioners for systemic tissue repair, hair regrowth, and anti-aging protocols. This delivers GHK-Cu systemically rather than locally. For autoimmune skin conditions, where the target tissue is accessible topically, the added risk and cost of injection is difficult to justify without evidence of superior efficacy.

Microneedling protocol: 0.5 to 1% GHK-Cu serum applied immediately after microneedling (0.5 to 1.0 mm needle depth). The micro-channels created by needling allow deeper penetration of the peptide into the dermis. Used for alopecia areata (scalp) and scarring. Sessions typically spaced 2 to 4 weeks apart. This approach combines two unproven interventions, which adds complexity without established benefit.

Cycling: Practitioners typically recommend 8 to 12 weeks of continuous use followed by a 4-week break for injection protocols. Topical use is generally continuous without cycling, mirroring cosmetic skincare application patterns.

Cost: OTC serums range from $30 to $80 per month. Compounded topical formulations cost $60 to $150 per month. Injectable GHK-Cu costs $100 to $200 per month from compounding pharmacies.

Safety and Limitations

What the Safety Data Shows

GHK-Cu has a long track record in cosmetic use. Millions of people apply copper peptide serums daily without significant reported adverse effects. Skin irritation at higher concentrations is the most common complaint, particularly in people with sensitive or already-inflamed skin.

No systemic toxicity has been reported from topical application. Injectable GHK-Cu has a shorter history and smaller user base. Practitioner reports describe it as well-tolerated, with occasional injection site reactions (redness, mild swelling) as the primary side effect.

The copper component deserves attention. Copper is an essential trace mineral, but it is also toxic at high levels. Oral copper supplementation at excessive doses causes gastrointestinal distress and, in extreme cases, liver damage. Topical GHK-Cu delivers minimal systemic copper. Injectable GHK-Cu at 1 to 2 mg per day delivers approximately 0.2 to 0.4 mg of elemental copper, which is within the normal dietary range (the recommended daily intake is 0.9 mg). Wilson's disease patients, who cannot properly metabolize copper, should avoid GHK-Cu in any form.

The Central Limitation: Gene Expression Is Not Clinical Proof

The GHK-Cu evidence base is built on a foundation of gene expression analysis and in vitro studies. This foundation is scientifically interesting and biologically plausible. It is not clinical proof.

Gene expression changes measured in cell culture tell you what a compound can do to isolated cells under controlled conditions. They do not tell you whether those changes occur in living tissue at achievable concentrations, whether they persist over time, or whether they translate to measurable clinical outcomes. The distance from "GHK-Cu modulates 4,000 genes in a favorable direction" to "GHK-Cu improves psoriasis" is enormous.

This is why every autoimmune skin condition receives Grade C. The mechanism is right. The gene expression profile is right. The direct evidence is absent. Honest grading demands distinguishing between these levels of evidence, even when the preclinical picture is compelling.

Drug Interactions

No formal drug interaction studies exist. Points of consideration:

Topical corticosteroids: GHK-Cu promotes collagen synthesis; corticosteroids cause skin atrophy through collagen degradation. Using them simultaneously on the same skin area creates opposing signals. Some practitioners suggest alternating rather than combining. No study has examined the interaction.

Biologic medications (adalimumab, secukinumab, dupilumab): These act systemically on immune pathways. Topical GHK-Cu acts locally on tissue repair. The mechanisms do not directly overlap, suggesting low interaction risk, but this is theoretical.

Retinoids (tretinoin): Both retinoids and GHK-Cu stimulate collagen synthesis and promote skin remodeling. Whether combining them produces additive benefits or excessive stimulation is unknown. Some skincare protocols include both, alternating morning and evening application.

Sourcing

GHK-Cu is widely available in cosmetic products, which is unusual among therapeutic peptides. The quality varies significantly. For cosmetic serums, look for products that list GHK-Cu (or copper tripeptide-1, the INCI name) early in the ingredient list and specify the concentration. Products listing it near the end of the ingredient list contain negligible amounts.

For compounded formulations, the standard quality indicators apply: a certificate of analysis from third-party testing, lot-specific documentation, and preparation by a licensed compounding pharmacy. For injectable GHK-Cu, sterility testing documentation is essential.

Building a GHK-Cu Protocol for Autoimmune Skin

Given the Grade C evidence across all autoimmune skin conditions, GHK-Cu should be positioned as an adjunct to established therapies, not a replacement.

Tier 1 (Foundation, strong evidence): Address the fundamentals first. The autoimmune diet (AIP elimination with Mediterranean principles), vitamin D optimization (Grade A), omega-3 fatty acids (Grade B), and stress management form the base of any autoimmune skin protocol. These have the strongest clinical evidence.

Tier 2 (Condition-specific, moderate evidence): Add condition-specific interventions with Grade B evidence. For psoriasis, this means curcumin and UV phototherapy. For eczema, probiotics and evening primrose oil. For alopecia areata, zinc and topical treatments with clinical data.

Tier 3 (Advanced, experimental): GHK-Cu belongs here. After establishing the foundation and condition-specific interventions, adding topical GHK-Cu as an adjunct is reasonable. The risk profile for topical use is low. The cost is moderate. The potential benefit, based on mechanistic plausibility, exists. Just understand that you are at the frontier of evidence, not on solid clinical ground.

Practical starting point: Begin with a cosmetic-grade GHK-Cu serum (0.1 to 1%) applied to affected areas once daily. Use for 12 weeks and assess subjective response. If tolerated and seemingly beneficial, discuss higher-concentration compounded formulations with your dermatologist. Document your response with photographs and symptom tracking.

For a personalized protocol that layers these tiers appropriately based on your specific condition, severity, and current medications, take the AutoimmuneFinder quiz. The protocol engine grades every intervention by evidence quality and builds condition-specific recommendations.

Frequently Asked Questions

Is GHK-Cu FDA-approved for autoimmune skin conditions?

No. GHK-Cu is not FDA-approved for any autoimmune skin condition or any therapeutic indication. It is widely available as a cosmetic ingredient in over-the-counter skincare products. Higher-concentration formulations are available through compounding pharmacies with a prescription. The February 2026 FDA peptide reclassification under RFK Jr. expanded access to several peptides through compounding pharmacies but did not grant FDA approval for therapeutic claims. All evidence for GHK-Cu in autoimmune skin conditions remains preclinical.

Can I apply GHK-Cu serum directly to psoriasis plaques?

This has not been studied in any controlled setting. OTC copper peptide serums (0.1 to 1%) are formulated for intact skin. Psoriatic plaques involve broken skin barrier, altered immune cell populations, and elevated inflammatory signaling. Whether GHK-Cu at cosmetic concentrations can modulate gene expression in this abnormal tissue environment is unknown. Some practitioners recommend compounded formulations at higher concentrations (1 to 3%) for targeted application, but this remains anecdotal. Do not discontinue prescribed psoriasis treatments in favor of GHK-Cu.

How does GHK-Cu compare to BPC-157 for tissue repair?

GHK-Cu and BPC-157 work through different mechanisms. GHK-Cu modulates gene expression broadly (4,000+ genes), promotes collagen remodeling, and enhances antioxidant defense. BPC-157 promotes tissue repair through VEGF-driven angiogenesis, nitric oxide system modulation, and tight junction restoration. BPC-157 has stronger animal model data for gut healing and wound repair. GHK-Cu has broader gene expression data and the practical advantage of topical availability. For skin conditions specifically, GHK-Cu is more directly applicable because it can be delivered to the target tissue topically. BPC-157 requires injection for systemic effects.

Is GHK-Cu safe for people with Wilson's disease?

No. Wilson's disease is a genetic condition that impairs copper metabolism, leading to toxic copper accumulation in the liver, brain, and other organs. GHK-Cu delivers copper to tissues. Even topical application delivers some systemic copper absorption. People with Wilson's disease, or those who carry Wilson's disease gene variants, should avoid all copper-containing compounds including GHK-Cu. If you are uncertain about your copper metabolism status, discuss with your physician before using copper peptide products.

Can I combine GHK-Cu with microneedling for alopecia?

Some practitioners use this combination, applying GHK-Cu serum immediately after microneedling the scalp. The rationale is that micro-channels enhance peptide penetration into the dermal papilla, where hair follicle stem cells reside. Microneedling alone has shown benefit for androgenetic alopecia (non-autoimmune pattern hair loss) in small trials. For autoimmune alopecia areata, neither microneedling nor GHK-Cu has been studied in a controlled trial. Combining two unproven interventions does not create proven therapy. If considering this approach, work with a dermatologist experienced in both microneedling and peptide protocols.

What is the strongest evidence for GHK-Cu in any context?

Wound healing carries the strongest evidence (Grade B). Arul et al. (2005) demonstrated that copper-containing wound dressings improved healing outcomes. Pickart's 2015 review compiled decades of wound healing data. Multiple cosmetic studies confirm skin remodeling effects at topical concentrations over 8 to 12 weeks. For autoimmune skin conditions specifically, no evidence exceeds Grade C. The jump from "proven wound healer" to "proven autoimmune skin therapy" requires clinical trials that have not been conducted.

The Bottom Line

GHK-Cu is a genuinely interesting compound. The gene expression data is broader and more consistently favorable than nearly any other peptide in the autoimmune space. The mechanisms align precisely with what autoimmune skin conditions need: reduced inflammation, restored barrier function, enhanced tissue repair, strengthened antioxidant defense. The topical availability makes it more accessible than injectable peptides.

None of that changes the evidence grade. Grade C means mechanistic and preclinical evidence only, without direct clinical data for the condition in question. Every autoimmune skin application of GHK-Cu sits at Grade C. The compound has been available for decades, which makes the absence of clinical trials more notable, not less. If GHK-Cu were truly transformative for psoriasis or eczema, someone would likely have published a case series by now.

Use GHK-Cu as a Tier 3 adjunct after establishing the dietary, supplement, and lifestyle foundations that have stronger evidence. Apply it topically to reduce risk. Track your response systematically. And recognize that you are participating in an informal experiment, not following a proven protocol.

For a complete, evidence-graded protocol tailored to your specific autoimmune condition, start with the AutoimmuneFinder quiz. It will build your personalized plan from Tier 1 foundations through Tier 3 advanced interventions, with honest grading at every step.